<DOC>
	<DOCNO>NCT02720107</DOCNO>
	<brief_summary>The purpose single visit extension study explore immune status RRMS patient treat least 48 month fingolimod . Long-term change T cell count compare short-term change immune status ( baseline month 6 ) treatment start fingolimod assess original Biobank study ( CFTY720DDE01 ) .</brief_summary>
	<brief_title>Follow Study Patients Fingolimod Who Were Enrolled Original Biobank Study ( CFTY720DDE01 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Written inform consent Participation study FTY720DDE01 Continuous intake fingolimod completion FTY720DDE01 study Pregnant nursing ( lactate ) woman Patients onset acute relapse must postpone evaluation Patients receive immunomodulating immunosuppressive MS treatment since completion CFTY720DDE01 study example : Natalizumab , Alemtuzumab , Dimethyl fumarate , Teriflunomide , intravenous Immunoglobulins , Mitoxantrone , Methotrexate , Azathioprine experimental immunomodulating/immunosuppressive therapy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>fingolimod ,</keyword>
	<keyword>Biomarker ,</keyword>
	<keyword>Multiple sclerosis ,</keyword>
	<keyword>Relapsing-remitting multiple sclerosis</keyword>
</DOC>